• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Galapagos NV

    12/10/25 4:10:54 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    S-8 1 tm2532625d1_s8.htm FORM S-8

    As filed with the U.S. Securities and Exchange Commission on December 10, 2025

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    GALAPAGOS NV

    (Exact name of registrant as specified in its charter)

     

     

    Belgium   Not applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    Generaal De Wittelaan L11 A3

    2800 Mechelen, Belgium

    +32 15 342 900

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Subscription Right Plan 2025 (A)

    Subscription Right Plan 2025 (B)

    (Full title of the plan)

     

    C T Corporation System

    28 Liberty Street

    New York, New York 10005

    (212) 590-9070

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Michael H. Bison, Esq.

    Janet Hsueh

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x   Accelerated filer ¨
           
    Non-accelerated filer ¨   Smaller reporting company ¨
           
          Emerging Growth Company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    PART I.

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II.

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed by Galapagos NV (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on March 27, 2025 (File No. 001-37384), which contains audited financial statements for the Registrant’s latest fiscal year for which such statements have been filed;

     

    (b) Our reports on Form 6-K furnished to the Commission on January 8, 2025; January 8, 2025, February 12, 2025; February 18, 2025; February 24, 2025; March 28, 2025; April 15, 2025; April 21, 2025, April 23, 2025, April 29, 2025, May 13, 2025; May 14, 2025; May 28, 2025; June 13, 2025; June 20, 2025, June 25, 2025, July 23, 2025, July 24, 2025, July 24, 2025, August 6, 2025; August 7, 2025; October 1, 2025; October 16, 2025, October 21, 2025, October 24, 2025, October 30, 2025, November 3, 2025, November 6, 2025 and November 26, 2025 (other than portions of each of the foregoing expressly excluded from incorporation by reference) (File No. 001-37384).

     

    (c) The description of the Registrant’s Ordinary Shares and American Depositary Shares contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on May 8, 2015 (File No. 001-37384), including any amendment or report filed for the purpose of updating such description.

     

     

     

     

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any report on Form 6-K furnished by the Registrant to the Commission after the date of this Registration Statement (or a portion thereof) is incorporated by reference in this Registration Statement only to the extent that the report expressly states that the Registrant incorporates it (or such portions) by reference in this Registration Statement and it is not subsequently superseded. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 4. DESCRIPTION OF SECURITIES

     

    Not applicable.

     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

     

    Not applicable.

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

     

    Under Belgian law, the directors of a company may be liable for damages to the company in case of improper performance of their duties. The Registrant’s directors may be liable to the Registrant and to third parties for infringement of the Registrant’s articles of association or Belgian company law. Under certain circumstances, directors may be criminally liable.

     

    The Registrant maintains liability insurance for the Registrant’s directors and officers, including insurance against liability under the Securities Act.

     

    The Belgian Companies and Associations Code includes a cap on liability for directors (including persons in charge of daily management) for any damages they cause due to mismanagement, including breaches of the articles of association and the Belgian Companies and Associations Code. This liability cap applies towards the company and third parties. For the Registrant, the cap amounts to €12,000,000.00 (subject to indexation). The cap applies irrespective of the number of claimants or defendants for the same (set of) facts. However, the cap does not apply to repetitive minor misconduct, serious error or cases of fraud. Furthermore, the cap does not apply to directors’ liability under the special liability regimes relating to payment of withholding tax, VAT and social security contributions.

     

    Certain of the Registrant’s non-executive directors may, through their relationships with their employers or partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of the Registrant’s Board of Directors.

     

    In the underwriting agreements the Registrant entered into in connection with its May 2015 global offering and its subsequent follow-on U.S. public offerings, the underwriters agreed to indemnify, under certain conditions, the Registrant, the members of the Registrant’s Board of Directors and persons who control the Registrant’s company within the meaning of the Securities Act against certain liabilities, but only to the extent that such liabilities are caused by information relating to the underwriters furnished to the Registrant in writing expressly for use in the Registrant’s registration statement and certain other disclosure documents.

     

     

     

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

     

    Not applicable.

     

    ITEM 8. EXHIBITS

     

    See the Exhibit Index below for a list of exhibits filed as a part of, or incorporated by reference into, this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

    ITEM 9. UNDERTAKINGS

     

    1. The undersigned Registrant hereby undertakes:

     

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (d) If the Registrant is a foreign private issuer, to file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished, provided that the Registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.

     

     

     

     

    2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
    Description
    4.1 Articles of Association, as amended (English translation)
    4.2(1) Form of Amended and Restated Deposit Agreement
    4.3(2) Form of American Depositary Receipt
    5.1 Opinion of Argo Law BV
    23.1 Consent of Deloitte Bedrijfsrevisoren BV
    23.2 Consent of BDO Bedrijfsrevisoren BV
    23.3 Consent of Argo Law BV (included in Exhibit 5.1)
    24.1 Power of Attorney (included on the signature page)
    99.1 Subscription Right Plan 2025 (A) (English translation)
    99.2 Subscription Right Plan 2025 (B) (English Translation)
    107 Calculation of Filing Fee Tables

     

    (1) Filed as Exhibit 4.1 to Registrant’s Registration Statement on Form F-1 (File No. 333-203435), filed with the U.S. Securities and Exchange Commission on April 30, 2015, and incorporated herein by reference.
    (2) Filed as Exhibit A to Registrant’s prospectus filed pursuant to Rule 424(b)(3) under the Securities Act (File No. 333-203584) filed with the U.S. Securities and Exchange Commission on October 15, 2018.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Mechelen, Belgium on December 10, 2025.

     

    GALAPAGOS NV    
           
    By: s/ Henry Gosebruch    
    Name: Henry Gosebruch    
    Title: Chief Executive Officer and Executive Director    

     

     

     

     

    POWER OF ATTORNEY

     

    We, the undersigned directors, officers and/or authorized representative in the United States of Galapagos NV, hereby severally constitute and appoint Henry Gosebruch and Aaron Cox, and each of them singly, our true and lawful attorneys-in-fact and agents, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of Galapagos NV, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated on December 10, 2025.

     

    Signature   Title
         

    /s/ Henry Gosebruch

    Henry Gosebruch

     

    Chief Executive Officer and Executive Director
    (Principal Executive Officer)

         

    /s/ Aaron Cox

    Aaron Cox

     

    Chief Financial Officer
    (Principal Financial and Accounting Officer)

         

    /s/ Jérôme Contamine

    Jérôme Contamine

      Chair of the Board of Directors
         

    /s/ Devang Bhuva

    Devang Bhuva

      Director
         

    /s/ Jane Griffiths

    Jane Griffiths

      Director
         

    /s/ Linda Higgins

    Linda Higgins, Ph.D

      Director
         

    /s/ Neil Johnston

    Neil Johnston

      Director
         

    /s/ Oleg Nodelman

    Oleg Nodelman

      Director
         

    /s/ Dawn Svoronos

    Dawn Svoronos

      Director
         
         
    Puglisi & Associates    
         

    By:

    /s/ Donald J. Puglisi               

      Authorized Representative in the United States
    Name: Donald J. Puglisi    
    Title: Managing Director    

     

     

     

    Get the next $GLPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

    High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematology (ASH) Annual Meeting. "The new and updated results from the Phase 2 ATALANTA-1 study demonstrate that GLPG5101 offers timely treatment with low rates of high-grade toxic

    12/8/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Receives Transparency Notifications from Bank of America

    Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on November 18 and November 19, 2025, from Bank of America Corporation indicating that it positively crossed the threshold of 5% of Galapagos' voting rights on November 12, 2025 following an acquisition of Galapagos' voting rights and equivalent financial instruments, and then subsequently fell below this threshold on November 14, 2025 following the disposal of such instruments. On November 14, 2025, the Bank of America Corporat

    11/26/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    SEC Filings

    View All

    SEC Form S-8 filed by Galapagos NV

    S-8 - GALAPAGOS NV (0001421876) (Filer)

    12/10/25 4:10:54 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    12/8/25 6:05:04 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    11/26/25 6:05:05 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

    New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board's composition with the Company's strategic direction and support its focus on transformational business development to build a pipeline of novel medicines in areas of high unmet medical need. Seasoned biopharma executive Dr. Neil Johnston has been appointed to the Board of Directors by way of co-

    10/30/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

    Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said

    7/23/25 4:03:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

    First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

    4/23/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

    Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

    2/12/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care